Conclusions: VinV -TAVI is widely performed, albeit in small numbers, in majority of centers in the Nordic countries. The short-term results are excellent on this high-risk patient population, demonstrating a low incidence of procedure-related complications. However, a number of patients are left with suboptimal systolic valve performance with unknown long-term effects, warranting a close surveillance after VinV-TAVI. Background: The last few years, transcatheter aortic valve implantation (TAVI) has evolved as a good alternative treatment for patients rejected or with high risk for aortic valve replacement (AVR). Very few studies report reasons for rejection for TAVI and the outcome of these rejected patients. The purpose of this study is to investigate the reasons for rejection for TAVI and compare survival between rejected and treated patients. Methods: In this retrospective single center study patients referred for TAVI between October 2007 and September 2011 are included. Reasons for rejection for TAVI were collected and survival was compared for conservative treatment with transfemoral or transapical TAVI and surgical AVR. Results: We included 374 patients(mean age 81 years, 49% male); 150 patients were rejected for TAVI. Reasons for rejection were: multiple comorbidities (24%), surgical candidate (14%), other heart disorders (poor left ventricular function and/or other valve abnormalities) (10%), asymptomatic or no severe aortic stenosis (7%), poor renal function, malignancy, severely impaired lung function, cognitive reasons, poor peripheral vessels and extreme high age. A total of 160 patients were treated by transfemoral TAVI and 64 patients by transapical TAVI. Patients treated by TAVI or surgically had a significant better 2-year survival than patients treated conservatively.
Conclusions:
There are many reasons for rejection for TAVI, but the main reason was multiple comorbidities. Patients with symptomatic severe aortic valve stenosis treated by TAVI or surgical have a better survival than patients treated conservative.
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Successful Background: Severe aortic regurgitation (AR), when intervention is required, is managed by surgical aortic valve replacement (SAVR). TAVR could be a valid "off label" option to treat severe AR for patients unsuitable for SAVR due to their high surgical risk. However, in severe AR, large aortic annulus and poor aortic valve calcifications made challenging TAVR. We hereby report our single centre experience of 8 cases (see Table) of AR in which surgical correction was excluded because of high predicted operative mortality. These cases were treated with TAVR using Medtronic CoreValve prostesis. Background: TAVR has become a standard therapy for patients with severe aortic stenosis considered to be inoperable or at very high risk for surgery. For both types of currently available prostheses (the selfexpanding CoreValve (Medtronic, Minneapolis, MN) and the ballon-expandable Edwards-Sapien XT (Edwards Lifesciences, Irvine, CA)) the standard procedure includes a balloon predilation as part of the procedure before implanting the actual device. Although predilation of the calcified valve may facilitate device placement, it bears a risk of stroke and conduction disturbances, two major drawbacks of this procedure. Methods: We performed a prospective study in 74 consecutive patients to investigate the feasibility and procedural results of direct implantation of the selfexpanding Medtronic CoreValve prosthesis without predilation. Results: A total of 74 consecutive patients implanted with a CoreValve aortic bioprosthesis were included in our study. Successful implantation was achieved in 73 (98.6%) of the patients. Postdilation was necessary in 27% of the cases. Evaluation of outcome after 30 days showed a stroke/TIA rate of 2.7% with a 1.3% rate of major stroke. At 30 days need for permanent pacemaker insertion post TAVR was 21.7% and overall mortality was 4.1 %. Procedural results showed an average implantation depth of 5.9Ϯ3.2 mm below the annulus line and a rate of postprocedural aortic regurgitation Ն grade 2 of 1.4%. Conclusions: Direct implantation of the CoreValve selfexpanding aortic bioprosthesis without predilation is feasible and may be a safe alternative to the standard procedure using predilation. Procedural results showed a low number of strokes and need for postinterventional pacemaker implantation. Prospective studies should be performed to compare both techniques of implantation with respect to periprocedural stroke rates and need for pacemaker implantation.
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Prognostic value of preinterventional troponin T levels in patients with severe aortic stenosis undergoing TAVR Background: Elevated concentrations of troponin T (cTnT) have prognostic impact in patients with aortic stenosis. For patients with high risk for conventional aortic valve replacement, transcatheter aortic valve replacement (TAVR) has become an established therapeutic option. Methods: We conducted a retrospective analysis in 201 consecutive patients scheduled for transfemoral TAVR and analyzed predictors, kinetics and prognostic values of preand postinterventional troponin T levels by using a high sensitive troponin T assay (Roche Diagnostics). Results: Patients with severe aortic stenosis had significantly elevated levels of cTnT detectable before TAVR. Postinterventional cTnT levels rose significantly about seven fold after transfemoral TAVR. Cardiac cTnT levels were highest at day 3 after TAVR (204 Ϯ 11 pg/ml (mean Ϯ SEM) compared to 43 Ϯ 3.1 pg/ml before TAVR) and steadily declined thereafter. Baseline renal function (pϭ0.011), the duration of intraprocedural rapid pacing (Pϭ0.0012) left ventricular mass (pϭ0.01) and baseline cTnT (pϭ0.0001) values were related to postinterventional cTnT release. Interestingly, Kaplan-Meier survival curve analysis revealed, that although cTnT levels were not predictive for shortterm mortality, preinterventional as well as postinterventional peak cTnT showed Background: Chronic obstructive pulmonary disease (COPD) has been associated with higher mortality following transcatheter aortic valve implantation (TAVI), but no data exist on the factors determining poorer outcomes and functional status improvement in these patients. Methods: A total of 210 consecutive patients (29.5% COPD) who underwent TAVI were studied. Baseline, procedural characteristics and follow-up (median of 12 [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] months) data were prospectively collected. Functional status, as evaluated by NYHA class, Duke Activity Status Index (DASI) and 6-minute walking test (6MWT), were performed at baseline and at 6-12 months. Results: COPD patients were younger, more frequently male and had a history of smoking, peripheral vascular disease and diabetes mellitus. Survival rates at 1 year after TAVI were 66% in COPD versus 85% in no-COPD patients (pϭ0.002). In multivariate analysis, COPD was an independent predictor of cumulative mortality following TAVI [HR: 2.49, 95% CI: 1.38-4.48, pϭ0.003]. Among COPD patients, a shorter distance in the pre-procedure 6MWT predicted cumulative mortality [HR: 1.25 for each decrease of 20 m, 95% CI: 1.05-1.49, pϭ0.014], whereas poorer baseline spirometry results (FEV1) determined a higher rate of periprocedural pulmonary complications [OR: 1.44 for each decrease of 5%, 95% CI: 1.03-2.0, pϭ0.031]. Baseline FEV1 Ͻ60% of predicted and a distance Ͻ150 m in the 6MWT best determined the occurrence of periprocedural pulmonary complications and midterm mortality, respectively. A significant improvement in functional status was observed following TAVI (pϽ0.001 for changes in NYHA class, DASI and 6MWT), without differences in the degree of functional improvement between COPD and no-COPD patients (pϭNS between groups for changes in NYHA, DASI and 6MWT). Conclusions: COPD was associated with a higher rate of mortality at midterm follow-up. Among COPD patients, a higher degree of airway obstruction and a lower exercise capacity determined a higher risk for pulmonary complications and mortality, respectively. In addition, COPD patients who survived after TAVI exhibited similar improvements in functional status as the rest of the study population. 
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Impact of Transcatheter Aortic Valve Implantation on Aortic-Mitral Valve Coupling
